• Legal
• Compounding
• FDA
• Science & evidence

BPC-157: is it legal? The 2026 answer

By Peptide Policy Watch staff · Published November 12, 2026 · 20 min read · 27 sources, 24 checked at the source

You've seen the pitch. A guy in a trench coat — sometimes a literal coat, sometimes just a website doing the same move — flips it open, and there it is: a little vial labeled BPC-157. For a long time, that gray-market sales pitch was a big part of how this peptide showed up in the wild.

The short answer to "is it legal?" is that it depends who's selling and how. BPC-157 is not an FDA-approved drug. [V] It is not a DEA controlled substance either. [V] What's new in 2026 is the other part: a legal compounding lane is opening.

The part most legal explainers skip

Plenty of people already use BPC-157. That is not a secret, and it is not new. A 2025 systematic reviewA review that collects studies on one question by a stated search method, often pooling their numbers. Glossary entry in HSS Journal described growing use among clinicians and athletes, even though the peptide has no FDA approval. [V] A 2026 review in Acta Orthopaedica Belgica likewise treated it as popular with athletic groups using it for musculoskeletal recovery, while noting that the human evidence is still thin. [V] In October 2026, CNBC, running an Associated Press report, wrote that peptides like these have found a foothold among Americans interested in building muscle, looking younger or raising energy, and named BPC-157 among the most popular in that group. [S] A long-running user community is part of the legal story. So is the gray market those people have often used — a neutral description of a market, not a verdict on the people in it.

BPC-157 is not a DEA controlled substance. I checked the federal schedules in 21 CFR Part 1308, which eCFR showed as up to date as of November 9, 2026, and the DEA's October 2026 list of scheduled substances. Neither names BPC-157. I also searched the same lists for common synonyms — body protection compound, pentadecapeptide, bepecin, and PL 14736 — and did not find those either. [V] Not being scheduled is not the same thing as FDA approval, and it is not permission for a seller to market an unapproved drug for human use. It does mean BPC-157 is not in the same legal bucket as a Schedule I or II drug.

The federal enforcement I can actually point to has targeted sellers and marketers, not individual users. FDA's 2026 warning letters in this file went to companies selling research-labeled peptides, after the agency looked at how the products were marketed. [V] I found no federal case against a person for personal possession of BPC-157. [U] That is a statement about what I found in public DOJ materials and news coverage as of November 12, 2026, not a promise about what a future case could look like, and not legal advice. State rules can differ. [U]

For someone holding a vial that did not come through a pharmacy, the issue that comes up again and again is product quality: whether the contents match the label, and how the product was made. The 2025 review noted that harm is possible from unregulated manufacturing, contamination, or the simple fact that clinical safety data in people are still missing. [V] That is a quality and evidence problem. It is not a claim that having the peptide is, itself, a crime.

In late October, HHS published a draft enforcement-discretion policy that names BPC-157 among six peptides a state-licensed 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry pharmacy could compound under set conditions, including a patient-specific prescription. [V] Enhanced, a publicly traded telehealth company, says that lane is already live on its platform, as of November 3. [V] Hims & Hers, another publicly traded telehealth company, has already put BPC-157 in its written plan, "to follow when allowable." [V] And the research is moving into people: two randomized, placebo-controlled trials are now on the federal registry, one of them recruiting. [V] That's real momentum. It is not an FDA approval, and neither trial has posted results yet. [V]

Facts are as of November 12, 2026. Sources, with retrieval dates, are at the bottom.

A legal compounding lane is opening

This is the change that makes 2026 different.

On October 30, 2026, HHS published a notice of availability in the Federal Register, at 91 FR 68526, for a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." [V] In that document, HHS describes a policy of enforcement discretion, while FDA develops the 503A bulks list through rulemaking, for a state-licensed pharmacy, and also for federal facilities and physicians who are licensed, compounding a drug from one of six peptide bulk substances in its Appendix A. [V] BPC-157 is the first name on that appendix; the others are TB-500, KPV, MOTS-c, semax and epitalon. [V]

The policy is a compounding lane, not a stamp of approval. FDA's own Q&A says compounded drugs lack FDA approval, so the agency does not check how safe, effective, or well made they are before they reach a patient. [V] HHS also wrote that the draft creates no rights for anyone and binds neither the department nor the public. [V] It can be revisited if a safety signal or a product-quality issue appears. [V] Closing the comment docket does not, by itself, add BPC-157 to the 503A bulks list. That list still has its own rulemaking. [V]

The draft still matters, because it describes the conditions under which HHS says it will stand down. There are ten of them. Among the ones that change the practical picture: the peptide has to be one of the six in Appendix A, in the identity and routes the policy names; the original manufacturer has to be registered with FDA and the lot needs a certificate of analysis; the finished preparation is a single active ingredient, not a blend; and it has to be compounded under 503A's patient-specific prescription requirement. [V] For BPC-157, the policy discussion focuses on BPC-157 acetate in named forms and routes. [V]

Where the ingredient stood before this is worth one clean paragraph, because it is the source of a lot of "banned, then unbanned" talk. FDA had placed BPC-157 on its Category 2An interim FDA group of nominated bulk ingredients that FDA has flagged for possible significant safety risks while its review continues. Glossary entry page — bulk substances nominated for compounding that the agency flagged as possibly presenting significant safety risks — from September 2023 until April 22, 2026. [V] The page, still current as of that April 22 date when I checked it today, now lists BPC-157 among nominations that were withdrawn. [V] Leaving that table is not an approval. The same page still carries FDA's concerns, including possible immune reactions for some routes, peptide-related impurities, and a line that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans." [V] I also did not find BPC-157 on FDA's 503A category list last updated May 14, 2026. [V] The HHS draft is doing a different job: describing enforcement discretion for 503A compounding while that bulks-list rulemaking proceeds.

Public comments close November 13, 2026, at 11:59 PM Eastern, on regulations.gov docket HHS-OASH-2026-0496. [V] I walk through what the comment window does and does not decide on the Federal Register comment-period page.

The big platforms are already lining up

The policy would not mean much if nobody used the lane. Companies already are.

On November 3, 2026, Enhanced Group said that, beginning that day, eligible customers could get all six of the HHS peptides — BPC-157 included — through licensed clinicians on its Live Enhanced telehealth platform. [V] The company says access is prescription-only, after a clinician reviews a person's health history and goals. It also says a state-licensed U.S. pharmacy makes and dispenses each one, using only the forms and routes named in the policy, and puts a single peptide in each preparation. [V] It also says the ingredients come from FDA-registered manufacturers that follow current good manufacturing practice, each with a certificate of analysis. [V] Those points track several of the conditions written into the HHS draft. [U]

Hims & Hers is the giant in this story, and it is not being shy about the destination. In an October 29, 2026 newsroom post, CEO Andrew Dudum previewed the company's Peptides+ specialty and wrote that it plans to offer sermorelin, glutathione, B12, NAD+ and L-carnitine, "with BPC-157 and TB-500 to follow when allowable." [V] On the November 9 earnings call, according to a third-party transcript, the company said the first phase of Peptides+ would arrive later this month, and that BPC-157 and TB-500 would be added "when the regulatory environment permits." [S] I have not found a Hims announcement that BPC-157 is live yet.

If HHS finalizes the policy as drafted, wider prescription access looks likely. The basis for that is already on the record: one public company says the six-peptide lane, BPC-157 included, is open through licensed clinicians and a state-licensed pharmacy, and another publicly traded telehealth company has already named BPC-157 in its plan for when the rules allow. [V] That is earned optimism about a compounding pathway. It is not a prediction that FDA will approve BPC-157 as a drug. No source I read says an approval is coming.

A scoreboard of who has announced what is in the peptide-rush tracker.

Early research is promising. Controlled trials are next.

Legal status and evidence are different questions, and both are moving.

Most of what researchers have published on BPC-157 is still early-stage work in cells and animals, the usual first step for any medicine. [V] The authors of a 2025 systematic review in HSS Journal included 36 studies and wrote that the evidence "suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries." [V] Thirty-five of those studies were preclinicalResearch done before any testing in people, such as lab-dish and animal studies. Glossary entry. [V] A 2026 review in Acta Orthopaedica Belgica, with searches through June 1, 2026, counted three published human studies and 30 participants in total, and rated the overall certainty of that evidence "very low." [V] Those two things can be true at once: the early research is promising, and the human evidence is still thin. The step that tests a promising signal is a controlled trial. That is the step BPC-157 is now reaching.

Two randomized, placebo-controlled trials are on ClinicalTrials.gov. A phase 2 study in acute hamstring strains (NCT07437547) is recruiting, with 120 people planned and an estimated primary completion date of February 14, 2027. [V] A University of Arkansas pilot after rotator cuff surgery (NCT07803250) is registered as randomized and placebo-controlled, not yet recruiting, with an estimated start of January 1, 2027. [V] Neither record has posted results. [V] I treat the hamstring trial's sponsor with some extra caution: the same company registered another study whose own summary calls the record "fictional," and I have not seen results or a publication from the hamstring study yet. [U]

I cover each of the published pilots, and those two registry records, in BPC-157 in people.

Is it FDA approved?

No. Approval means a company filed an application, FDA reviewed the clinical data, and the product received a label that spells out approved uses and warnings. BPC-157 has none of that. [V] The 2025 HSS Journal review describes it as a substance without FDA approval. [V]

A July 2026 meeting of FDA's Pharmacy Compounding Advisory Committee sometimes gets retold as "FDA approved it this summer." That meeting was about the 503A bulks list for compounding, not drug approval. [V] Press reports said the committee recommended adding BPC-157, 8 to 6 with one abstention. [S] FDA's own meeting page says advisory committees make non-binding recommendations, and the agency generally follows them but is not legally bound to. [V] As of my check, that page still had no posted minutes or official vote summary. [V] A panel vote is advice. It is not an approval, and it is not a bulks-list decision.

For the list-by-list version of the approval question, the earlier page is still useful: Is BPC-157 FDA approved?. This page is the legal-status answer.

"Research use only" is a label, not a license

This is where the guy in the trench coat usually does his best work. A website sells a vial, stamps "for research use only" or "not for human consumption" on the page, and dares you to treat that line as a legal category. FDA does not.

In the regulations, "research use only" is a phrase that belongs to certain lab diagnostic products, not to medicines taken by people. [V] What FDA looks at is intended use, read from the whole picture: claims, advertising and how a product is sold. [V] In a March 31, 2026 warning letter, and again in an August 24, 2026 letter, FDA noted those research-use disclaimers and still concluded, from the sellers' websites, that the peptides were intended as drugs for human use. It called them unapproved new drugs. [V]

The humor writes itself, and it is aimed at the sales pitch, not at anyone looking for a legitimate path. A disclaimer on a product page is not a license to sell an unapproved drug. The research-use-only decoder traces where those label lines come from in the regulations.

Sale for human use is restricted. So is personal importation.

Federal drug rules here are mostly about who may make a product, how it is marketed, and whether it may be introduced into interstate commerce. Popularity does not change those rules. A compounded BPC-157 preparation under the HHS draft still requires a patient-specific prescription from a 503A setting that meets the conditions. [V] Sale for human use is restricted: the open lane the draft describes is that pharmacy path, not a general okay to sell the peptide as a drug. [V] FDA's personal-importation page generally treats bringing unapproved drugs into the United States for one's own use as not allowed, because those products often lack FDA approval. A drug approved only in another country still counts as unapproved here. [V]

The possession question is the one covered earlier: BPC-157 is not a controlled substance, and I found no federal case against a person for personal possession. [V] [U] The compounding pages, the HHS draft, and the warning letters I read still do not draw a one-sentence bright line for every product, shipment or sale, and I am not going to invent one. [U] State law can add its own rules. [U] None of this is legal advice.

The cleaner federal picture is still the one in the headline: it depends who's selling and how. A prescription filled by a state-licensed 503A pharmacy under the HHS conditions is the lane the draft describes. A research-use website marketing a vial for human use is the fact pattern FDA has already treated as an unapproved new drug. [V] Are peptides legal in the US? sorts that distinction across peptides, not just this one.

Sport has its own rulebook

Even if a compounding lane opens, sport does not move with it.

WADA's 2026 Prohibited List, which I read today from WADA's own PDF, names BPC-157 in class S0, non-approved substances. [V] S0 covers a pharmacological substance that no government health authority has currently approved for use as a human therapy, and the class is prohibited at all times. [V] WADA published the 2027 List on September 21, 2026; it takes effect January 1, 2027. [V] USADA, which covers Olympic and Paralympic athletes in the United States, has a dedicated BPC-157 page that confirms the S0 listing and says FDA and other health authorities have not approved the peptide for clinical use in people. [V] USADA also says a therapeutic-use exemption for BPC-157 is unlikely to be approved because permitted alternatives exist, though it considers each application case by case. [V]

College athletes answer to a different list. The NCAA bans a class covering peptide hormones and growth factors, plus related substances and their mimics, and its table of examples names BPC-157. [V] The NCAA also says that list of examples is not complete, and that a substance chemically or pharmacologically related to a banned class is banned as well. [V]

If you compete in a tested sport, this is a separate "no," and it does not wait on HHS. The WADA explainer and the NCAA and league-rules page have the name-by-name comparisons.

How to tell the real deal from the trench coat

If the legal lane is opening, the useful skill is telling that lane apart from the old sales pitch.

The path the HHS draft describes is unglamorous, and that is the point. It runs through a licensed clinician, a patient-specific prescription, and a state-licensed 503A pharmacy that can meet the policy's conditions: the right peptide, the named identity and routes, a documented manufacturer and certificate of analysis, a single-ingredient preparation, and a product labeled as a compounded drug, not for resale. [V] Enhanced's November 3 description is built around that same shape — prescription only, a licensed U.S. pharmacy, one peptide per preparation, ingredients from an FDA-registered manufacturer with a certificate of analysis. [V] Hims, in its October 29 preview, also framed its plan around independent providers and licensed pharmacies. [V]

The trench-coat version usually looks like the opposite. No named pharmacy. No prescription. A "research use only" or "not for human consumption" line doing work a disclaimer can't do. Health claims on a product page that, in FDA's 2026 warning letters, were enough to treat research-labeled peptides as unapproved new drugs. [V] Nobody here is judging a reader for asking the question. The joke is on the coat, not on you.

BPC-157 is also often discussed as a pair with TB-500; that pairing has its own page in the "Wolverine stack" article.

What to watch next

The near-term calendar is full, and none of it is an FDA approval date.

Watch the policy, the platforms and the trials. If the draft is finalized as written, the prescription lane stays open and, given who is already lining up, wider access looks likely. [V] If HHS revises it, the conditions could tighten or the list could change. [V] The registered trials are how the promising early research gets a harder test. [V] None of those watch-items is the same thing as FDA approving BPC-157.

The legal question people type into a search box has a 2026 answer, and it is more interesting than a blunt yes or no. BPC-157 is not a controlled substance, and it is not FDA-approved. Sale for human use is restricted, a gray market already exists, and a legal compounding lane is opening. It still depends who's selling and how. The trench coat is not that lane.

Sources (retrieved November 12, 2026 unless noted)

1. Federal Register, 91 FR 68526, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," FR Doc. 2026-22192, notice of availability, published October 30, 2026 (retrieved November 12, 2026) [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
2. HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," policy text and appendices, including Appendix A (BPC-157 among six peptides) and the ten conditions (retrieved from the agency PDF October 29, 2026; notice re-checked November 12, 2026) [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
3. Regulations.gov, docket HHS-OASH-2026-0496; comment window two weeks after the October 30 Federal Register publication, listed on the docket as closing at 11:59 PM Eastern on November 13, 2026 (docket close time from the regulations.gov document record; Federal Register API comment-close field still empty, comments still accruing, checked November 12, 2026) [V] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
4. FDA, "Compounding and the FDA: Questions and Answers," current as of 09/16/2025 (retrieved November 12, 2026) [V] — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
5. FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (Category 2 page), content current as of 04/22/2026 (retrieved November 12, 2026) [V] — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
6. FDA, 503A bulk drug substances category list (PDF), updated May 14, 2026 (retrieved October 26, 2026) [V] — https://www.fda.gov/media/94155/download
7. FDA, "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee," content current as of 08/06/2026 [V] — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
8. AJMC (secondary), "FDA panel backs 6 peptides for compounding," July 31, 2026 [S] — https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
9. FDA, "Personal Importation," current as of 08/18/2025 (retrieved November 12, 2026) [V] — https://www.fda.gov/industry/import-basics/personal-importation
10. FDA, warning letter 721806, Gram Peptides, March 31, 2026 (retrieved November 12, 2026) [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
11. FDA, warning letter 735063, Peptide Partners LLC, August 24, 2026 (retrieved November 12, 2026) [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
12. eCFR, 21 CFR 809.10, labeling for in vitroDone in a dish or test tube, using cells or tissue outside a living body. Glossary entry diagnostic products [V] — https://www.ecfr.gov/current/title-21/section-809.10
13. eCFR, 21 CFR 201.128, meaning of "intended uses" [V] — https://www.ecfr.gov/current/title-21/section-201.128
14. Enhanced Group, "Enhanced Provides Clinician-Led Access to Six New Peptides," investor press release, November 3, 2026 (retrieved November 12, 2026) [V] — https://investors.enhanced.com/enhanced-provides-clinician-led-access-to-six-new-peptides/
15. Andrew Dudum, "Expanding Safe Access to Peptides," Hims & Hers newsroom, October 29, 2026 (retrieved November 12, 2026) [V] — https://news.hims.com/newsroom/expanding-safe-access-to-peptides
16. Benzinga, "Hims & Hers Health Q3 2026 Earnings Call Transcript," November 9, 2026, 6:09 PM ET [S] (third-party transcript, not an official company transcript) — https://www.benzinga.com/news/26/11/63076365/hims-hers-health-q3-2026-earnings-call-transcript
17. Vasireddi N, et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal, 2025 (PubMed abstract, retrieved October 25, 2026) [V] — https://pubmed.ncbi.nlm.nih.gov/40756949/
18. Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine," Acta Orthopaedica Belgica 92(3), 2026, published online October 8, 2026 [V] — https://doi.org/10.52628/92.3.15837
19. ClinicalTrials.gov, NCT07437547, "BPC 157 for Acute Hamstring Muscle Strain Repair," status recruiting, last updated February 27, 2026 (retrieved November 12, 2026) [V] — https://clinicaltrials.gov/study/NCT07437547
20. ClinicalTrials.gov, NCT07803250, "Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery," first posted September 3, 2026, status not yet recruiting (retrieved November 12, 2026) [V] — https://clinicaltrials.gov/study/NCT07803250
21. WADA, 2026 List of Prohibited Substances and Methods, official PDF, in force January 1, 2026 (retrieved November 12, 2026) [V] — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
22. WADA, "WADA publishes 2027 Prohibited List," news release, September 21, 2026 (retrieved November 12, 2026) [V] — https://www.wada-ama.org/en/news/wada-publishes-2027-prohibited-list
23. USADA, "BPC-157: Experimental Peptide Creates Risk for Athletes" (retrieved November 12, 2026) [V] — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
24. NCAA, "NCAA Banned Substances" page, peptide hormones class examples including BPC-157 (retrieved November 12, 2026) [V] — https://www.ncaa.org/sports/2015/6/10/ncaa-banned-substances.aspx
25. eCFR, 21 CFR Part 1308, Schedules of Controlled Substances, displayed as up to date as of November 9, 2026; Title 21 last amended November 6, 2026 (retrieved November 12, 2026; text search found no BPC-157, body protection compound, pentadecapeptide, bepecin, or PL 14736) [V] — https://www.ecfr.gov/current/title-21/chapter-II/part-1308
26. DEA Diversion Control Division, "Lists of: Scheduling Actions, Controlled Substances, and Regulated Chemicals" (Orange Book), October 2026 (retrieved November 12, 2026; same name search, no hits) [V] — https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf
27. Associated Press via CNBC, "Trump administration advances plan for peptide drugs favored by RFK Jr.," October 15, 2026 (retrieved November 12, 2026) [S] — https://www.cnbc.com/2026/10/15/peptides-trump-rfk-jr-maha.html

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits